1,495 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
ABBV AbbVie Inc. $95.37 $144.42B Sell
Article Searches
Dividend Sensei's Portfolio Update 56: The Smart Way To Win A $1.6-Billion Jackpot https://seekingalpha.com/article/4213281-dividend-senseis-portfolio-update-56-smart-way-win-1_6-billion-jackpot?source=feed_all_articles Oct 22, 2018 - With the Mega Millions jackpot at $1.6 billion, lotto fever is sweeping the country.Just remember that even if you beat the odds, lottery winners often regret their large windfalls. Many large jackpot
Baby DivHut Dividend Income Portfolio Update Q3 2018 https://seekingalpha.com/article/4213072-baby-divhut-dividend-income-portfolio-update-q3-2018?source=feed_all_articles Oct 22, 2018 - With nine months of the year already behind us, it is time for me to highlight baby DivHut's quarterly dividend income/portfolio progress. Generally speaking, there is not much change in his portfolio
FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers http://www.gurufocus.com/news/755466/fda-accepts-application-for-abbvies-imbruvica-in-specific-blood-cancers Oct 18, 2018 - FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers, Stocks: ABBV,XSWX:RO, release date:Oct 18, 2018
Novartis Reports Positive Long-Term Data From Cosentyx Trials http://www.zacks.com/stock/news/328979/novartis-reports-positive-long-term-data-from-cosentyx-trials?cid=CS-ZC-FT-328979 Oct 18, 2018 - Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.
FDA accepts AbbVie's application for Imbruvica + Gazyva in certain blood cancers https://seekingalpha.com/news/3398006-fda-accepts-abbvies-application-imbruvica-gazyva-certain-blood-cancers?source=feed_news_all Oct 17, 2018 - Under Priority Review status, the FDA accepts for review AbbVie's (NYSE:ABBV) marketing application seeking approval for IMBRUVICA (ibrutinib), combined with Roche's (OTCQX:RHHBY) GAZYVA (obinutuzumab
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq http://www.zacks.com/stock/news/328751/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq?cid=CS-ZC-FT-328751 Oct 17, 2018 - EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S. https://www.wsj.com/articles/biosimilar-humira-goes-on-sale-in-europe-widening-gap-with-u-s-1539687603?mod=pls_whats_news_us_business_f Oct 16, 2018 - Cheaper copies of the world’s biggest-selling drug will roll out across Europe after a key European patent for Humira expires, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug.
It's Literally The Best Time Ever To Buy This High-Yield Blue Chip https://seekingalpha.com/article/4212001-literally-best-time-ever-buy-high-yield-blue-chip?source=feed Oct 16, 2018 - The stock market's recent sell-off has caused even Grade A dividend aristocrats to go on sale.AbbVie has been hammered for months by numerous concerns over biosimilar rivals to Humira and changes in r
Beat The Recession With Dividends - Part 3 https://seekingalpha.com/article/4211917-beat-recession-dividends-part-3?source=feed_all_articles Oct 16, 2018 - One needs much more than $59,000 to make $33,726 in dividend income immediately.If one looks to dividend growth instead of yield, it may take years to decades to accumulate enough dividend income.If a
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends https://seekingalpha.com/article/4211834-10-safer-dividend-healthcare-wallstars-gain-12minus-23-percent-per-broker-october-targets?source=feed_all_articles Oct 16, 2018 - October's top net gain safer Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.WallStars all s

Pages: 123456...150

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ABT Abbott Laboratories NYSE $67.67 $118.71B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
SNY Sanofi NYSE $43.75 $109.14B
MRK Merck & Company, Inc. NYSE $70.42 $187.28B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for AbbVie